Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Laroprovstat, an investigational oral PCSK9 inhibitor, was well tolerated and produced substantial LDL cholesterol reductions, especially when combined with rosuvastatin, supporting further development for hypercholesterolemia.
Gene therapy for cardiomyopathy is moving from concept to clinic, but durable benefit will depend on solving delivery, immunogenicity, cargo, and safety barriers in the failing human heart.
TRISCEND II showed that transcatheter tricuspid valve replacement with EVOQUE markedly reduced tricuspid regurgitation and improved clinical outcomes across baseline severity levels, with a stronger signal for benefit in massive or torrenti
A large multicohort and experimental study suggests the cTnI/cTnT ratio is biologically informative, separates acute from chronic myocardial injury, and modestly improves type 1 versus type 2 MI discrimination.
In symptomatic HFpEF with atrial functional mitral regurgitation, sacubitril/valsartan improved exercise hemodynamics, peak VO2, symptoms, biomarkers, and stress-induced MR burden over 6 months versus standard care.
COPD exacerbations significantly increase cardiovascular risk for months. This article examines the link between COPD and heart disease, emphasizing proactive screening during flare-ups and evidence-based prevention strategies to improve su
A large Dutch primary care cohort links subclinical hyperthyroidism to higher risks of atrial fibrillation, heart failure, and all-cause mortality, with particularly notable relative risks in younger adults and in patients with more strongl
CARDIO-TTRansform is a global Phase 3 trial evaluating eplontersen’s efficacy and safety in reducing cardiovascular events in transthyretin amyloid cardiomyopathy patients receiving standard care, including TTR stabilizers. With 1,432
A 10-year Medicare study reveals women face higher immediate risks during TAVI procedures but demonstrate better long-term survival than men, despite declining representation in treatment.
This review synthesizes the TAILORED-CHIP trial results with recent evidence on antiplatelet modulation, highlighting the challenges of balancing ischemic and bleeding risks in high-risk PCI populations.
In suspected myocardial infarction, hs-cTnT-gen6 showed diagnostic accuracy comparable to gen5, produced fewer myocardial injury classifications, and supported highly sensitive ESC 0/1-hour and 0/2-hour rule-out and rule-in pathways using a
ORBITA-FIRE study reveals personalized physiological thresholds for angina that are lower than current diagnostic standards. These thresholds vary during exercise and predict PCI treatment success, challenging universal ischemia-based guide
This review synthesizes recent evidence comparing ‘mothership’ and ‘drip-and-ship’ strategies in acute ischemic stroke, highlighting functional benefits of direct transport and the critical 43-minute delay threshold.
An ex vivo human skeletal muscle study suggests that myosin ATPase inhibition with mavacamten normalizes excessive resting ATP consumption in HFrEF myofibres, identifying a mechanistically novel strategy to address peripheral metabolic inef
In Kenyan outpatient clinics, an AI-enabled ECG algorithm showed strong discrimination for left ventricular systolic dysfunction, with 95.6% sensitivity and 99.1% negative predictive value against echocardiography.
In Medicare patients undergoing femoropopliteal revascularization, drug-coated devices were not associated with higher long-term mortality, supporting the safety of paclitaxel-coated technology after years of regulatory concern.
In a prospective multicenter evaluation, the EXCOR Active Driver supported pediatric VAD care with no major device malfunctions and excellent short-term survival, while addressing a major unmet need in mobility and day-to-day function.
This review explores how PRMT9-mediated symmetric dimethylation of STAT1 serves as a critical check on proinflammatory macrophage activation, offering a novel therapeutic target for mitigating cardiac injury following myocardial infarction.
In a multicenter retrospective study, early mechanical thrombectomy within 12 hours of pulmonary embolism diagnosis improved pulmonary artery pressure reduction and reduced intubation, but did not significantly lower in-hospital mortality.
In PoPH, PAH-specific therapy did not worsen oxygenation overall, although responses varied widely. Hemodynamic changes influenced gas exchange, and some patients developed new intrapulmonary vascular dilatations during follow-up.
Open language-specific specialty feeds and department pages.